Abstract
Newer markers of bone formation and bone resorption are now available. Alone these new markers do not appear to be useful to diagnose metastatic bone disease. Several markers appear to be of prognostic importance and correlate with the extent of tumour in the skeleton. Serial monitoring of bone markers may be useful to monitor the efficacy of bisphosphonate and/or systemic therapy of both lytic and blastic bone metastases.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 181-185 |
| Number of pages | 5 |
| Journal | Cancer Treatment Reviews |
| Volume | 27 |
| Issue number | 3 |
| DOIs | |
| State | Published - Jun 2001 |
All Science Journal Classification (ASJC) codes
- Oncology
- Radiology Nuclear Medicine and imaging